{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-dateTabled=2018-04-26", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-dateTabled=2018-04-26", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-dateTabled=2018-04-26&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=0&max-dateTabled=2018-04-26", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-dateTabled=2018-04-26", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-dateTabled=2018-04-26", "items" : [{"_about" : "http://data.parliament.uk/resources/892165", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/892165/answer", "answerText" : {"_value" : "<p>From 1 April 2018, the National Living Wage and National Minimum Wage increased above inflation to give more than two million of the lowest paid workers a pay rise of over 2 per cent in real terms. Over the next 12 months, full time workers aged 25 and over on the National Living Wage will see their earnings grow by more than £600.<\/p><p> <\/p><p>In the longer term, the Government\u2019s ambitious, modern Industrial Strategy sets out a long-term plan to boost the productivity and earning power of people throughout the UK. It sets out how we will help businesses create better, higher-paying jobs with investment in the skills, industries and infrastructure of the future.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3936", "label" : {"_value" : "Biography information for Andrew Griffiths"}
        }
        , "answeringMemberConstituency" : {"_value" : "Burton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Griffiths"}
        , "dateOfAnswer" : {"_value" : "2018-05-03", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-03T15:33:37.663Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-04-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Low Pay"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking to tackle low pay.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "138424"}
    , {"_about" : "http://data.parliament.uk/resources/872272", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872272/answer", "answerText" : {"_value" : "<p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and<\/p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).<\/p><p> <\/p><p>The following treatments are currently under consideration by NICE:<\/p><p> <\/p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;<\/p><p>- Inotuzumab ozogamicin for treating r/r ALL; and<\/p><p>- Blinatumomab in other extended indications in ALL.<\/p><p> <\/p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Clofarabine for treating ALL in children after two therapies; and<\/p><p>- Nelarabine for treating ALL after two therapies.<\/p><p> <\/p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-04-03", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "134187"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-04-03T13:25:08.103Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Acute Lymphoblastic Leukaemia: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134186"}
    , {"_about" : "http://data.parliament.uk/resources/872273", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872273/answer", "answerText" : {"_value" : "<p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and<\/p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).<\/p><p> <\/p><p>The following treatments are currently under consideration by NICE:<\/p><p> <\/p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;<\/p><p>- Inotuzumab ozogamicin for treating r/r ALL; and<\/p><p>- Blinatumomab in other extended indications in ALL.<\/p><p> <\/p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Clofarabine for treating ALL in children after two therapies; and<\/p><p>- Nelarabine for treating ALL after two therapies.<\/p><p> <\/p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-04-03", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "134186"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-04-03T13:25:08.167Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Acute Lymphoblastic Leukaemia: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with Refractory B-cell Acute Lymphoblastic Leukaemia have been unable to access treatments for that condition.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134187"}
    , {"_about" : "http://data.parliament.uk/resources/872274", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872274/answer", "answerText" : {"_value" : "<p>Most new drugs and significant licence indications are assessed by the National Institute for Health and Care Excellence (NICE) through its technology appraisal programme, through which NICE has been able to recommend a significant number of drugs for the treatment of rare cancers and other diseases for routine use on the National Health Service. NICE also operates a separate Highly Specialised Technology evaluation programme for the evaluation of a very small number of treatments for very rare diseases.<\/p><p>The methods and processes NICE uses in the development of its guidance are internationally respected, have been developed through extensive engagement with a full range of stakeholders, including the Department, and are regularly reviewed to ensure that they remain fit for purpose.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-04-03", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-04-03T13:25:57.05Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer and Rare Diseases: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NICE appraisals for new treatments for rare (a) diseases and (b) cancers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134188"}
    , {"_about" : "http://data.parliament.uk/resources/872275", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872275/answer", "answerText" : {"_value" : "<p>The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence on matters related to medicines pricing and patient access to new treatments. We will consider all relevant issues in upcoming discussions with the pharmaceutical industry on medicines pricing arrangements for 2019 onwards to succeed the current Pharmaceutical Price Regulation Scheme.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-03-29T14:02:10.2Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) NHS England and (b) NICE on the development of (a) multi-indication pricing, (b) outcomes-based pricing and (c) annuity deals for new treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134189"}
    , {"_about" : "http://data.parliament.uk/resources/872373", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872373/answer", "answerText" : {"_value" : "<p>Since April 2017, there are currently 27 drugs in 42 indications that are funded by the Cancer Drugs Fund (CDF). A full list of current and previous CDF drugs can be viewed at the following link:<\/p><p> <\/p><p><a href=\"https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/\" target=\"_blank\">https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/<\/a><\/p><p> <\/p><p>The latest published spend for the first six months of 2017/18 implies a circa £76 million of unused funding for that period against the CDF. The quarterly activity report is a snapshot of CDF spend at a point in time and the spend figure will increase as more drugs are added to the fund. The link to the report can be found here:<\/p><p> <\/p><p><a href=\"https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf\" target=\"_blank\">https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-03-29T13:51:19.143Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what drugs have been funded through the Cancer Drugs Fund this year; and how much funding remains in that Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134287"}
    , {"_about" : "http://data.parliament.uk/resources/872374", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872374/answer", "answerText" : {"_value" : "<p>This information is not held centrally. NHS England is currently developing plans for national data collection.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-03-29T14:00:43.397Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many people have accessed the Cancer Recovery Package in the last 12 months; and what proportion of those people had blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134288"}
    , {"_about" : "http://data.parliament.uk/resources/872375", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872375/answer", "answerText" : {"_value" : "<p>Every cancer patient will be eligible for the Recovery Package intervention regardless of their treatment status.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-03-29T13:57:20.463Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer: Mental Health Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 March 2018 to Question 132195, on Haematological Cancer: Mental Health Services, whether patients diagnosed with blood cancer but not yet starting treatment will be eligible for the Cancer Recovery Package.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134289"}
    , {"_about" : "http://data.parliament.uk/resources/872376", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872376/answer", "answerText" : {"_value" : "<p>The Cancer Patient Experience Survey 2016 results show that 90% of respondents said that they were given the name of a clinical nurse specialist who would support them through their treatment. NHS England is working alongside Health Education England to expand the number of Clinical Nurse Specialists (CNS) and develop clear CNS competencies and routes into training. This will ensure every cancer patient has access to a CNS or other support worker by 2021.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-03-29T13:56:27.02Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Nurses"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether every patient diagnosed with cancer receives support from a clinical nurse specialist; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134290"}
    , {"_about" : "http://data.parliament.uk/resources/872380", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872380/answer", "answerText" : {"_value" : "<p>The 10 multidisciplinary diagnostic centres or \u2018rapid assessment and diagnostic centres\u2019 have been described in the Progress Report on the cancer strategy published by NHS England in October 2017 at the following link:<\/p><p> <\/p><p><a href=\"https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf\" target=\"_blank\">https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf<\/a><\/p><p> <\/p><p>The evaluation of the centres is being undertaken by the Accelerate, Co-ordinate, Evaluate Partnership, which will publish its final report in December 2018.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-03-29T13:55:02.697Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 March 2018 to Question 132100, on Haematological Cancer, whether he or NHS England plan to publish information on the work of multidisciplinary diagnostic centres before December 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134294"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=1&max-dateTabled=2018-04-26", "page" : 0, "startIndex" : 1, "totalResults" : 242, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}